TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study published Nov. 4 found that tau accumulated at more than twice the rate in people with early-onset Alzheimer’s than in older-onset patients, with wider spread through the brain. The results may help explain differences in disease progression and symptoms, but the study did not test treatments or establish why tau changes faster.
A study comparing patients with early-onset Alzheimer’s and those whose symptoms began at age 65 or later found that tau accumulated at more than twice the rate in the younger-onset group and spread more widely through the brain. Published Nov. 4 in Science Translational Medicine, the findings may help explain why early-onset disease can progress faster and involve language, visual-spatial or executive difficulties, although the research did not test treatments or prove what causes the difference.
The researchers examined 390 people with early-onset Alzheimer’s in the Longitudinal Early-Onset Alzheimer’s Disease Study, whose average age was 59, and compared them with 211 people with late-onset disease in the Alzheimer’s Disease Neuroimaging Initiative, whose average age was 78. Early-onset disease was defined as symptoms starting before 65. All participants had mild cognitive impairment or mild dementia attributed to Alzheimer’s, and PET scans showed amyloid, an early disease biomarker.
A subset of participants had repeat tau PET scans over an average of two to three years, allowing the team to track changes over time. The report describes more extensive tau deposits in the early-onset group as well as faster accumulation and broader spread. The study is described by its authors as the largest comparison of tau in early- and late-onset Alzheimer’s to date. It was supported by the National Institute on Aging.
Among early-onset patients, one in five had a presentation not dominated by memory problems. By contrast, more than 99% of late-onset patients with documented presentations had a memory-dominant form. The report describes possible non-memory symptoms such as difficulty interpreting visual information despite a normal eye exam, judging distances, reading, retrieving words, following long sentences, planning or adapting to change. These are patterns observed in the study population, not symptoms that apply to every person with Alzheimer’s.
Tau Differences May Shape Symptoms
The results add evidence that early- and late-onset Alzheimer’s may differ in more than age at diagnosis. The researchers found a stronger contrast between the groups for tau than for amyloid, according to the report. Tau is a hallmark protein associated with Alzheimer’s, and its accumulation was more closely related to worsening memory in the study, senior author Gil Rabinovici said.
That pattern could help researchers investigate why younger patients may experience faster progression or symptoms involving language, vision and spatial processing, and executive function. It also matters for research design: if tau changes more rapidly in early-onset disease, studies that combine patients across age-of-onset groups may need to account for those differences when measuring disease progression.
The findings also raise a treatment question, not an answer. The two drugs approved to slow Alzheimer’s progression described in the report target amyloid. The study did not test whether younger patients respond differently to those drugs, nor whether tau-targeting treatment would improve outcomes. The authors say the results support examining tau-focused or combined-treatment approaches in clinical trials.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms (Up to 1,718 sq ft)
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
Levoit Vital 100S-P Air Purifier with Washable Pre-Filter
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Tau
Alzheimer’s disease is commonly associated with both amyloid and tau, but this study focused on comparing tau patterns by age when symptoms began. Participants already had evidence of amyloid on PET scans, while repeat tau scans in a subset gave researchers a way to examine changes over time rather than relying only on a single scan.
Early-onset Alzheimer’s accounts for about 5% of Alzheimer’s patients, according to the source report, and people in this group are more likely than older patients to have symptoms beyond memory problems at first. The study excluded people with known disease-causing mutations, which are carried by a small minority of early-onset patients, according to first author Konstantinos Chiotis.
The research, “Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease,” was published in Science Translational Medicine on Nov. 4, 2026. Its comparison drew on two separate research cohorts, with different average ages and study names, rather than a single randomized experiment. The findings describe disease patterns; they do not establish that age itself causes faster tau accumulation.
“A key question is whether other genetic factors explain this more aggressive tau pathology.”
— Konstantinos Chiotis, MD, PhD, first author
Causes and Treatment Effects Remain Open
The study found a difference in tau accumulation but did not determine why it occurs. Researchers do not yet know whether genetic factors beyond rare known mutations account for the more aggressive tau patterns, or what other biological influences may contribute. The study excluded people with known disease-causing mutations, so its findings do not address that group.
The analysis also does not show that faster tau accumulation alone causes faster clinical decline, or that every younger patient will have a non-memory presentation. Although the researchers related tau accumulation to progression in memory loss, the report provides no treatment comparison and does not establish whether tau-targeting therapies, alone or combined with amyloid drugs, would benefit this group. The supplied report does not give the full numerical estimates, confidence ranges or detailed methods for the rate comparison.
Genetic Studies and Tau Trials
Researchers say further work is needed to test whether genetic differences help explain tau patterns in early-onset disease and to identify possible treatment targets. Chiotis said understanding how genetics shape the differences seen in younger patients could point to new targets, but no specific genetic cause was established by this study.
The findings may also inform clinical trials that assess treatments aimed at tau, including combinations that target both tau and amyloid. Such trials would need to test whether these approaches are safe and effective, and whether younger patients benefit differently. No results from a treatment trial are reported here; the current development is evidence about disease progression, not a change in recommended care.
Key Questions
What did the study find about tau in early-onset Alzheimer’s?
Researchers reported that tau accumulated at more than twice the rate in the early-onset group compared with the late-onset group, and spread more widely through the brain. The study tracked tau changes in a subset using repeat PET scans over an average of two to three years.
How did the study define early-onset Alzheimer’s?
It defined early-onset disease as symptoms beginning before age 65. Late-onset disease referred to symptoms beginning at age 65 or later.
Were symptoms different between the groups?
In the study, one in five early-onset patients had a presentation not dominated by memory problems. More than 99% of late-onset patients with documented presentations had a memory-dominant form. The study does not mean every patient will follow these patterns.
Does the research show that tau treatments work better for younger patients?
No. The researchers did not test Alzheimer’s treatments. They said the findings raise questions for future trials, including trials of treatments targeting tau or both tau and amyloid.
Why does tau accumulate faster in early-onset disease?
The cause is not known. Researchers raised the possibility that genetic factors may contribute, but this study did not identify an explanation.
Source: news-medical.net
